Exelixis Inc

EXEL · Moat type: REGULIERUNG

MoatScore

10/10

Fair Value

76 USD

Margin of Safety

+27.2 %

Rating

STARK

Exelixis Inc. develops and markets oncological active substances, whose revenues derive primarily from the sale of the kinase inhibitor Cabozantinib (in multiple indications such as renal cell and hepatocellular carcinoma) as well as from license and milestone payments from international partnerships.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.